Almirall’s Post

Discover our latest case study that delves into the complexities of a large-scale global Phase III Biosimilar Dermatology Trial. The study showcases how COD’s strategies streamlined regulatory processes, enhanced site management, optimized patient selection and retention, and effectively managed investigational products (IP). By addressing these critical areas, the trial not only achieved its scientific objectives but also set a new benchmark for efficiency and success in the field of Biosimilar development. To know more about our Clinical Solutions, write to us at bd@cod-research.com Designing Therapies for Future #BiosimilarDevelopment #PhaseIIIClinicalTrial #DermatologyResearch #RegulatoryStrategy #SiteManagement #PatientRetention #ClinicalTrials #CODResearch

#IPC Honorary Founder Chris Griffiths OBE shares insights into the evolution of dermatology services in Manchester, highlighting the growing role of nurses in care teams and the transformative impact of biologics on their contributions. He also explores the shift from traditional care models to outreach and rapid-access services, showcasing how psoriasis service design can drive research and training opportunities: https://lnkd.in/gkk6N9_7 Watch recordings from all four webinars in the 2024 series, now available for free on the #IPCWebsite: https://lnkd.in/gHF-YfGX #IPCEvent #PsoriasisExpert

🌟 Important Update from Sun Pharma! 🌟 🚀 Sun Pharma has achieved a major milestone with the US FDA's approval of Leqselvi (Deuruxolitinib) for treating severe alopecia areata, a condition causing patchy baldness. This breakthrough therapy offers new hope to patients seeking effective treatment options. 🌿💊 💡 This approval highlights Sun Pharma's dedication to advancing dermatology care and addressing unmet medical needs. Stay tuned as we prepare to make Leqselvi available to patients in need! 🌍💪 #SunPharma #DermatologyCare #AlopeciaAreata #FDAApproval #MedicalAdvancement

🧬 𝐖𝐡𝐲 𝐝𝐨𝐞𝐬 #𝐌𝐨𝐥𝐞𝐜𝐮𝐥𝐚𝐫𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐩𝐥𝐚𝐲 𝐚𝐧 𝐞𝐬𝐬𝐞𝐧𝐭𝐢𝐚𝐥 𝐫𝐨𝐥𝐞 𝐢𝐧 𝐝𝐞𝐫𝐦𝐚𝐭𝐨𝐥𝐨𝐠𝐲? In recent decades, the development of novel and highly specific therapeutics has increased a lot in dermatology, especially for conditions such as melanoma, psoriasis, and eczema. However, diagnostic techniques have not advanced at the same pace, preventing highly specific therapeutics from reaching their full potential. This large gap between diagnostics and therapeutics is being bridged by DNA- and RNA-based molecular diagnostics. Dermagnostix started on building this bridge with #PsorX – the worldwide first molecular test for the differential diagnosis of psoriasis and eczema! You want to join our journey of #MovingDiagnosticFrontiers in dermatology? Subscribe to our #newsletter: https://lnkd.in/eRCXcTVB #BeyondTheSurface #Psoriasis #Eczema

As we begin this video series, Level-Up Investigator Christopher Bunick, MD, PhD, an Associate Professor of Dermatology at Yale University, shares valuable insights on atopic dermatitis care standards based on study data. #Dermatology #AtopicDermatitis #HealthcareResearch Christopher Bunick

ENTOD Pharmaceuticals has appointed Dr Anish Desai as Scientific and Research Adviser, leveraging his 30+ years of expertise to drive innovation in ophthalmology, ENT, and dermatology, advancing impactful healthcare solutions. Head to our website to read more: https://lnkd.in/gjbc69rz Dr. Anish Desai. MD. Entod Pharmaceuticals Nikkhil K Masurkar #indiamedtoday #healthcare #healthcarenews #healthcareupdates

Just published in Dermatology and Therapy!! “Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis” I’m happy to share our last publication (with Anne Sohrt Petersen, Ulla Ivens, PhD, Albert Bosch Vilaró, John Stinson and Jose Manuel Carrascosa Carrillo), where we conducted a matching adjusted indirect comparison of the efficacy at week 32 of tralokinumab and dupilumab in combination with topical corticosteroids (TCS). The results of this analysis showed that tralokinumab and dupilumab, both in combination with TCS, have similar efficacy at 32 weeks. Full paper: https://lnkd.in/d7t4XVEY #atopicdermatitis #biologictherapy

I am constantly amazed by Rubedo Life Sciences and by our team as we advance our journey and mission to develop the new frontier of #LongevityMedicines. We have a unique opportunity to start with the skin tissue, testing at the same time both therapeutics in chronic inflammatory dermatological conditions and in skin aging, tip of the spear for many others tissues to follow. Really exciting to move our first steps into the clinic with a Phase 1 basket trial in patients for the program #RLS1496, a proprietary, novel, first-in-class #GPX4modulator targeting pathologic senescent cells that came out of our AI-Enabled Single-Cell Multi-Omics Drug Discovery Platform #Alembic.

We are thrilled to see that LEO Pharma and Gilead Sciences have entered into a strategic partnership to accelerate the development of LEO Pharma's oral STAT6 program aimed at treating patients with inflammatory diseases. Under this partnership, Leo Pharma, backed by LEO Foundation // LEO Fondet and Nordic Capital, has the option to co-commercialise dermatology indications outside the US. Additionally, the company retains global rights to topical formulations of the dermatology program. "This partnership acknowledges Leo Pharma's scientific capabilities and strengthens our commitment to innovate for people with skin diseases," said CEO Christophe Bourdon. Read more: https://lnkd.in/dBxeAkiK

SEE THIS VERY IMPORTANT REPOST FOR CLINICIANS! This is a very useful quick reference chart on vaccines and systemic therapies commonly used in dermatology and also by clinicians in other disciplines of medical practice. #dermsquared